Efficacy and Safety Study of Romiplostim in Paediatrics with Immune Thrombocytopenia

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005019-96

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective is to describe the percentage of time that pediatric subjects with immune thrombocytopenia (ITP) have a platelet response in the first 6 months from the start of treatment with romiplostim.


Critère d'inclusion

  • Immune Thrombocytopenia (ITP) in Paediatric Subjects